EuropaBio & Biosimilar Medicines

01.12.2008

EuropaBio & Biosimilar Medicines

Welcome letter by EuropaBio

Biotechnology has enabled the discovery of treatments for some of the most serious diseases known to man – worldwide, the lives of over 325 million people have been transformed by the availability of a growing number of biotechnology medicines.
Today patients have access to more than 155 biotechnology drugs and vaccines, and medical science is working to increase that number every day. There are more than 418 biotechnology medicines in development, covering more than 100 diseases. These include 210 medicines for cancer, 50 for infectious diseases, 44 for autoimmune diseases, and 22 for AIDS/HIV and related conditions.
 
As the exclusive rights (patents and other data protection) for certain biological medicines expire, similar biological medicines or “biosimilars” are being developed. Some of these are already on the market in Europe. This document is intended to explain the complexities of biotech medicines, including biosimilar medicines, and to give an insight into what patients, healthcare professionals and other interested individuals should know about biotech and biosimilar medicines.
 
Willy DeGreef
Secretary General, Europabio